Abstract
Although metformin is widely used for treatment of type 2 diabetes (T2D), its glucose-lowering mechanisms remains unclear. Using the glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) antagonist exendin(9-39)NH2, we tested the hypothesis that postprandial GLP-1-mediated effects contribute to the glucose-lowering potential of metformin in T2D. In a randomised, placebo-controlled, double-blind, crossover study, 15 individuals with T2D (median HbA1c 50 mmol/mol (6.7%), BMI 30.1 kg/m2, age 71 years) underwent, in randomised order, 14 days of metformin and placebo treatment, respectively. Each treatment period was preceded by 14 days without any glucose-lowering medicine and concluded by two 4-hour mixed meal tests performed in randomised order and separated by >24 hours with either continuous intravenous exendin(9-39)NH2 or saline infusion. Compared to placebo, metformin treatment lowered fasting plasma glucose (mean of differences (MD) 1.4 mmol/l×min (95% CI 0.8-2.0)) as well as postprandial plasma glucose excursions during both saline infusion (MD 186 mmol/l×min (95% CI 64-307)) and exendin(9-39)NH2 infusion (MD 268 mmol/l×min (95% CI 108-427)). The metformin-induced improvement in postprandial glucose tolerance was unaffected by GLP-1R antagonization (MD 82 mmol/l×min (95% CI -6,564-170)). Metformin treatment increased fasting plasma GLP-1 (MD 1.7 pmol/l×min (95% CI 0.39-2.9)) but did not affect postprandial GLP-1 responses (MD 820 pmol/l×min (95% CI -1,750-111)). Using GLP-1R antagonization, we could not detect GLP-1-mediated postprandial glucose-lowering effect of metformin in individuals with T2D. We show that two weeks of metformin treatment increases fasting plasma GLP-1, which may contribute to metformin's beneficial effect on fasting plasma glucose in T2D. Clinicaltrials.gov NCT03246451.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.